Home Application of proteomics to prenatal screening and diagnosis for aneuploidies
Article
Licensed
Unlicensed Requires Authentication

Application of proteomics to prenatal screening and diagnosis for aneuploidies

  • Chan-Kyung J. Cho and Eleftherios P. Diamandis EMAIL logo
Published/Copyright: October 20, 2010

Abstract

Current screening for fetal aneuploidies relies on biochemical and ultrasound measurements, and the sensitivity and specificity needs to be improved to reduce the number of pregnant women subjected to invasive diagnostic procedures, such as amniocentesis. Proteomic technologies enable new strategies for discovering biomarkers from complex biological fluids in a high-throughput and sensitive manner. Since mass spectrometry-based techniques allow for both qualitative and quantitative analysis of a given proteome, they have been widely used to resolve and compare the proteome of maternal plasma, serum, urine, cervical-vaginal fluid, and amniotic fluid. Comparisons of proteomes of normal fluids with those from aneuploidy pregnancies have revealed a host of candidate markers that still need to be verified. In parallel with proteomics, there is interest in other emerging techniques, such as RNA-SNP analysis or quantitation of fetal DNA by shotgun sequencing. Although these genomic techniques hold much promise, discovery of additional markers via quantitative proteomic comparisons could drastically improve current conventional screening at reasonable cost. Proteomics-based biomarker discovery is applicable to detection of not just aneuploidies, but also other pregnancy-related diseases.


Corresponding author: Dr. Eleftherios P. Diamandis, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 6th Floor, Room 6-201, Box 32, 60 Murray Street, Toronto, ON M57 3L9, Canada Phone: +1 416-586-8443, Fax: +1 416-619-5521

Received: 2010-6-23
Accepted: 2010-7-14
Published Online: 2010-10-20
Published in Print: 2011-01-01

©2011 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Publisher's Note
  2. Publisher's Note
  3. Editorials
  4. Full-Disclosure in Industry-Sponsored Laboratory Medicine Research Studies: Statement by the Consortium of Laboratory Medicine Journal Editors
  5. Association of malignant mesothelioma and asbestos related conditions with ovarian cancer: shared biomarkers and a possible etiological link?
  6. Pharmacogenomics of alcohol metabolism: implications for legal testing
  7. Reviews
  8. Non-invasive assessment of liver fibrosis: it is time for laboratory medicine
  9. Application of proteomics to prenatal screening and diagnosis for aneuploidies
  10. Opinion Paper
  11. Harmonization of free thyroid hormone tests: a mission impossible?
  12. Genetics and Molecular Diagnostics
  13. A polymorphism in the 5’ UTR of the DEFB1 gene is associated with the lung phenotype in F508del homozygous Italian cystic fibrosis patients
  14. Interaction between COX-2 G-765C and smoking in relation to coronary artery disease in a Chinese Uighur population
  15. General Clinical Chemistry and Laboratory Medicine
  16. Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis
  17. Determination of daptomycin in human plasma by liquid chromatography-tandem mass spectrometry. Clinical application
  18. A high-performance liquid chromatographic method for benznidazole quantitation in plasma of patients with Chagas disease
  19. Use of serum free light chain analysis and urine protein electrophoresis for detection of monoclonal gammopathies
  20. Interlaboratory study of free monoclonal immunoglobulin light chain quantification
  21. Serum zinc-α2-glycoprotein concentrations in patients with non-alcoholic fatty liver disease
  22. Testosterone is an independent determinant of bone mineral density in men with type 2 diabetes mellitus
  23. Introduction of a new cobalamin (vitamin B12) assay: lessons from a flawed validation study
  24. Prevalence and course of pseudothrombocytopenia in outpatients
  25. Use of the CD19 count in a primary care laboratory as a screening method for B-cell chronic lymphoproliferative disorders in asymptomatic patients with lymphocytosis
  26. Validation and Outcome Studies Reference Values and Biological Variations
  27. Age- and gender-dependent changes in circulating concentrations of tumor necrosis factor-α, soluble tumor necrosis factor receptor-1 and sulfated glycosaminoglycan in healthy people
  28. Gender-specific association of serum uric acid with metabolic syndrome and its components in juvenile obesity
  29. Cross-sectional study of biomarkers of exposure and biological effect on monozygotic twins discordant for smoking
  30. Cancer Diagnostics
  31. Evaluation of ovarian cancer biomarkers in subjects with benign asbestos-related pleural diseases
  32. Development of a fluorescent microsphere immunoassay for cystatin B (CSTB) in serum of patients with hepatocellular carcinoma
  33. Letters to the Editor
  34. Factors reducing hemolysis rates in blood samples from the emergency department
  35. Low concentrations of serum n-3 polyunsaturated fatty acids in non-alcoholic fatty liver disease patients with liver injury
  36. Crystal-associated pseudoeosinophilia of synovial fluid
Downloaded on 6.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2011.002/pdf
Scroll to top button